Natco Pharma Limited · NSE:NATCOPHARM
Natco Pharma — Q4 FY25 & FY25 Earnings Presentation
9 slides from Natco Pharma's earnings presentation, May 28, 2025
Slide 1: Exchange filing cover letter for earnings presentation
28th May, 2025 Corporate Relationship Department Manager – Listing M/s. BSE Ltd. M/s. National Stock Exchange of India Ltd Dalal Street, Fort “Exchange Plaza”, Bandra – Kurla Complex Mumbai 400 001 Bandra (E) Mumbai 400 051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir/Madam, Sub: - FY 24-25 Ea
Slide 2: NATCO Pharma Limited Earnings Presentation Q4 FY25 & FY25
NATCO Pharma Limited Earnings Presentation Q4 FY25 & FY25
Slide 3: Disclaimer
Disclaimer THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF NATCO PHARMA LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general background information about the
Slide 4: Q4FY25 & FY25 - Key Business & Consolidated Financial Highlights
Q4FY25 & FY25 - Key Business & Consolidated Financial Highlights Total Revenue stood for Q4FY25 at INR 6,511atMn| INRPharma 12,873Export Mn | Pharma ExportatFormulations Formulations INR 2,858 Mnat |INR 10,525Formulations Domestic Mn | Domestic Formulations Revenue at INR 961 Mn Revenue at 994 Mn |
Slide 5: Q4FY25 & FY25 - Quarterly and Full year Performance
Q4FY25 & FY25 - Quarterly and Full year Performance Revenue Breakup (%) - Q4FY25 Revenue Division (INR Mn) Q4FY25 Q4FY24 Q3FY25 Revenue Division (INR Mn) FY25 FY24 7.7 1.2 3.6 API Revenue 464 500 666 API Revenue 2,018 2,492 Formulation Formulation 81.8 Formulation – Exports (incl profit Formulation
Slide 6: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Profit & Loss Statement (INR Mn) Q4FY25 Q4FY24 Q3FY25 Profit & Loss Statement (INR Mn) FY25 FY24 Total Revenue 12,873 11,103 6,511 Total Revenue 47,840 41,269 Total Expenses (before finance cost and depreciation) 6,729 5,710 4,360 Total Expenses (before finance c
Slide 7: Key product pipeline - USA
Key product pipeline - USA Para IVs in the pipeline, with 28 over 20 FTFs (incl. Sole and 13 Approved (either tentative or fully) Shared) Key Solo FTFs (Para IV) in the pipeline Key Para IV products in the pipeline (Filing on NCE-1) date Therapeuatic segment/ Therapeuatic segment/ Brand Molecule Bra
Slide 8: Our NCE | Cell & Gene Therapy Investments
Our NCE | Cell & Gene Therapy Investments 1 eGenesis 3 Cellogen Therapeutics • Invested INR 68 crore in a biotechnology company Invested INR 15 crore with a Company, which is at the focused on xenotransplantation, by developing safe forefront of using advanced cellular engineering methods and effect
Slide 9: Earnings Call Details - Q4FY25 & FY25
Earnings Call Details - Q4FY25 & FY25 The Earnings call to discuss the operational and financial performance of the company with Mr. Rajeev Nannapaneni, Vice Chairman and Chief Executive Officer and Mr. Rajesh Chebiyam, Executive Vice President, Crop Health Sciences are as below: Details of the Earn